-

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Global Payments (GPN) Buyout of EVO Payments (EVOP)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the directors of EVO Payments, Inc. (“EVO”) (NASDAQ: EVOP) breached their fiduciary duties to its shareholders in approving a merger with Global Payments Inc. (“Global Payments”) (NYSE: GPN) for inadequate consideration. If you are an EVO shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

Scott+Scott is investigating whether EVO’s board of directors failed to maximize the value of EVO for the benefit of EVO’s shareholders in connection with its announced merger with Global Payments, in breach of their fiduciary duties to EVO’s shareholders, and whether EVO’s shareholders have suffered damages as a result.

On August 2, 2022, EVO announced it had reached an agreement to be bought out by Global Payments for $34 per share. The transaction is valued at approximately $4 billion.

What You Can Do
If you are an EVO shareholder, you may have legal claims against EVO’s directors. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

About Scott+Scott
Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, and Ohio.

Attorney Advertising

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
844-818-6982
jpettigrew@scott-scott.com

Scott+Scott Attorneys at Law LLP

NASDAQ:EVOP

Release Versions

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
844-818-6982
jpettigrew@scott-scott.com

More News From Scott+Scott Attorneys at Law LLP

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Treace Medical Concepts, Inc. (NASDAQ: TMCI)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Middle District of Florida against Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) o...

Shareholder Alert: Scott+Scott Attorneys at Law LLP Issues Corrected Notice to Clarify Deadline To Seek Appointment As Lead Plaintiff In Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”) issues this corrected notice to clarify the deadline to seek appointment as Lead Plaintiff in the securities class action against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) and other defendants. On March 27, 2025, Scott+Scott filed a securities class action lawsuit in the United States District Court for the Southern District of New York against Actinium (NYSE American: ATNM), and certain of its former...

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20...
Back to Newsroom